7 Key Figures From Gilead Sciences' Q2 Earnings

July 26, 2016 1:01 AM

28 0

Gilead Sciences' Harvoni sales weighed on results, but the company's balance sheet strengthened.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the biggest companies in biopharma, but that hasn't kept investors from selling its shares this year. Stiffening competition in the market for hepatitis C treatment has caused sales of its multibillion-dollar hepatitis C drug Harvoni to falter, and that'...

Also read: Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

Read more

To category page